A Phase 2 interventional study of cortexolone 17α-propionate in Acne Vulgaris, sponsored by Cassiopea SpA. Completed at 10 sites in 2 countries. Open to participants aged 9 Years to 11 Years. Per ClinicalTrials.gov, last updated 2020-11-20.
Sponsored by Cassiopea SpA · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.
Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 13th largest by enrollment, is one of 3 that started in 2016, is one of 3 in phase 2, and was the 6th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:
Pak Emirates Military Hospital · Sites in Pakistan
Ages 12–55
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Sites in China
Ages 12+
Allied Hospital Faisalabad · Sites in Pakistan
Ages 15+
Khyber Teaching Hospital
Ages 12–35
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Ages 12+
By country, each count listing its studies:
Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 5 · Phase 4 7
First in 2012; this study’s year is marked. 3 started in 2016.
This study's enrollment of 27 is below the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 50 across the 19 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 19 have an industry lead sponsor. The 8 most frequent:
Cassiopea SpA is the lead sponsor of 7 studies on the registry; none are open to participants now.
Cassiopea SpA has 4 studies filed under Acne Vulgaris — fewer than ten, so there is no comparison to draw.
3 of the studies testing clascoterone in Acne Vulgaris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07673094Khyber Teaching HospitalComparison of Topical Clascoterone and Adapalene for Mild Acne Vulgaris | 2027-02 |
| NCT07883538Pak Emirates Military HospitalComparison of Topical Clascoterone 1% Cream Versus Adapalene 0.1% Cream in the Treatment of Mild-to-Moderate Acne Vulgaris | 2027-04-30 |
| NCT07881315Allied Hospital FaisalabadClascoterone Versus Clindamycin Added to Adapalene/Benzoyl Peroxide for Moderate Facial Acne | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies testing clascoterone in Acne Vulgaris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in pediatric patients 9 to less than 12 years of age with acne vulgaris. Adrenal suppression effects and systemic safety are an important safety concern. The current study is designed to investigate these potential concerns under maximal use conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical CB-03-01 (cortexolone 17α-propionate) cream containing 1% active drug applied to the face and trunk twice daily for 14 days
Drug: cortexolone 17α-propionate
CB-03-01 cream is a topical steroidal antiandrogen that is being developed for the potential treatment of acne vulgaris, an androgen-dependent skin disorder.
Also known as: CB-03-01
Change in HPA Axis Response as Measured by CST
Measurement of serum cortisol concentrations after stimulation of the adrenal cortex with cosyntropin (Cosyntropin Stimulation Test - CST). HPA axis suppression is defined as a post-stimulation serum cortisol level ≤ 18 μg/dL at Day 14.
Time frame: Pre- and Post-CST on Day 14
Evaluate Trough Plasma Concentrations
Trough (single blood draw approximately 12 hours post the most recent dose) measurements of cortexolone 17α-propionate (clascoterone) concentration in plasma at Screening, Baseline, Day 7 and Day 14.
Time frame: 14 Days
| Milestone | CB-03-01 Cream, 1% |
|---|---|
| Started | 27 |
| Completed | 27 |
| Not completed | 0 |
Measurement of serum cortisol concentrations after stimulation of the adrenal cortex with cosyntropin (Cosyntropin Stimulation Test - CST). HPA axis suppression is defined as a post-stimulation serum cortisol level ≤ 18 μg/dL at Day 14.
| mcg/dL | CB-03-01 Cream, 1% |
|---|---|
| Cortisol level (Pre-CST) | 12.50 ± 4.90 |
| Cortisol level (Post-CST) | 22.95 ± 3.20 |
Trough (single blood draw approximately 12 hours post the most recent dose) measurements of cortexolone 17α-propionate (clascoterone) concentration in plasma at Screening, Baseline, Day 7 and Day 14.
| ng/mL | CB-03-01 Cream, 1% |
|---|---|
| Screening | 0.0 ± 0.0 |
| Baseline (Day 1) | 0.027 ± 0.136 |
| Day 7 | 0.577 ± 1.01 |
| Day 14 | 0.606 ± 0.701 |
Collected over 14 Days or up to 42 days for those with laboratory evidence of adrenal suppression (i.e., post-stimulation serum cortisol level ≤18 μg/dL at Day 14).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CB-03-01 Cream, 1% | 0/27 (0%) | 0/27 (0%) | 5/27 (18.5%) |
| Event | CB-03-01 Cream, 1% |
|---|---|
| ACTH stimulation test abnormalInvestigations | 4/27 |
| LeukopeniaBlood and lymphatic system disorders | 1/27 |
Safety Population, defined as all enrolled subjects who were dispensed and applied at least one dose of the test article. All enrolled subjects were included in the safety population.
| Age, Continuous(years) | CB-03-01 Cream, 1% |
|---|---|
| Mean | 10.2 ± 0.9 |
| Sex: Female, Male(Participants) | CB-03-01 Cream, 1% |
|---|---|
| Female | 22 |
| Male | 5 |
| Ethnicity (NIH/OMB)(Participants) | CB-03-01 Cream, 1% |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 20 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | CB-03-01 Cream, 1% |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 25 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Baseline HPA Axis Response(mcg/dL) | CB-03-01 Cream, 1% |
|---|---|
| Cortisol Level (Pre-CST) | 13.53 ± 4.53 |
| Cortisol Level (Post-CST) | 24.87 ± 3.70 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2016 to primary completion in Mar 2018, 16 months.
Results were first posted in Oct 2020, 2 years 6 months after primary completion. A results delay was requested in Jun 2019.
Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 16 months is above that.
Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clascoterone
Cassiopea SpA